Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non Operating Income (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Non Operating Income for 6 consecutive years, with -$275000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income fell 1157.69% year-over-year to -$275000.0, compared with a TTM value of $6.8 million through Sep 2025, up 440.34%, and an annual FY2024 reading of $6.7 million, up 523.2% over the prior year.
  • Non Operating Income was -$275000.0 for Q3 2025 at Barinthus Biotherapeutics, down from $320000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $7.8 million in Q4 2021 and bottomed at -$9.3 million in Q1 2021.
  • Average Non Operating Income over 5 years is $790812.5, with a median of $688500.0 recorded in 2022.
  • The sharpest move saw Non Operating Income soared 330.97% in 2024, then plummeted 1157.69% in 2025.
  • Year by year, Non Operating Income stood at $7.8 million in 2021, then tumbled by 37.79% to $4.8 million in 2022, then crashed by 169.52% to -$3.4 million in 2023, then soared by 299.02% to $6.7 million in 2024, then tumbled by 104.11% to -$275000.0 in 2025.
  • Business Quant data shows Non Operating Income for BRNS at -$275000.0 in Q3 2025, $320000.0 in Q2 2025, and $75000.0 in Q1 2025.